medigraphic.com
Academia Mexicana de Neurología, A.C.

2007, Number 1

<< Back Next >>

Rev Mex Neuroci 2007; 8 (1)

Evaluation of patients with relapsing-remitting multiple sclerosis on treatment with Interferon beta 1-a 12 million units

Porras-Betancourt M, Núñez-Orozco L

Language: Spanish
References: 46
Page: 8-17
PDF size: 418.59 Kb.


ABSTRACT

Introduction: Multiple sclerosis (MS) is a non-curable demyelinating disease of the central nervous system, most commonly affecting young women, which causes a very important disability, but whose natural history can be modified with some treatments, such as interferon beta. Objectives: To evaluate burst rates before and after the treatment, as well as the associate disability. Material and methods: We reviewed patient files with diagnosis of relapsing-remitting multiple sclerosis (RRMS) clinically defined with characteristic lesions in RMI and were on treatment with interferon beta 1-a 12 million U. We compared the burst/year rate and EDSS score before and after the treatment. Results: We evaluated 53 patients attended at neurology service of the National Medical Center 20 de Noviembre, since 1990 to 2005; 18 men and 35 women, with diagnosis of RRMS were divided in 3 groups according to the time of progression before the start of the treatment: 8249 5 years, between 5 and 10 years and > 10 years; the initial disability rate in EDSS was between 1.0 and 9.0. Interferon beta 1-a 12 million U SC three times a week was administered for a mean time of 3.519 years. The median of burst/year rate before treatment was 3 in the group 1, 3 in the group 2 and 4 in the group 3, and after starting treatment bursts were 0 in the group 1, 0 in the group 2, and 1 en the group 3 (p = 8249 0.005). We observed a direct correlation between disability score and time of progression before treatment. Disability rate before and after treatment had no significant difference, but the lack of change in the score results an indicator of disease stability. Conclusion: Interferon beta 1-a 12 million units is useful to reduce burst rate and delay progression of the disease.


REFERENCES

  1. Blevins G, Martin R. Future immunotherapies in multiple sclerosis. Semin Neurol 2003; 23: 147-58.

  2. Kantarci OH, Weinshenker BG. Natural History of Multiple Sclerosis. Neurol Clin 2005; 23: 17-38.

  3. Polman CH, Uitdehaag BM. Regular Review: Drug treatment of multiple sclerosis. BMJ 2000; 321: 490-4.

  4. Rivera OVM. En: Núñez Orozco L (ed.). El manejo integral de la esclerosis múltiple. 1a. Ed. Editorial Prado. 2003.

  5. McDonald WI. The history of multiple sclerosis. In: Cook SD (ed.). Handbook of multiple sclerosis. 3rd. Ed. Ed. Marcel Dekker, Inc.; 2001, p. 1-14.

  6. García-Pedroza F. Neuroepidemiología de la esclerosis múltiple. En: Núñez OL. El manejo integral de la esclerosis múltiple. 1a. Ed. Editorial Prado; 2003, p. 7-18.

  7. Alter M, Olivares L. Multiple sclerosis in Mexico. An epidemiologic study. Arch Neurol 1970; 23: 451.

  8. Corona T, Rodríguez JL, Otero E, Stoop L. Multiple Sclerosis in Mexico. Epidemiology and clinical funding at the National Institute of Neurology and Neurosurgery (Mexico). Neurología (España) 1996; 11: 170-3.

  9. González O, Sotelo J. Is the frequency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry 1995; 59: 528-30.

  10. Schumacher GA, Beebe G, Kibler RF, Kurlant LT, Kurtzke JF, McDowell F. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Med 1965; 122: 552-66.

  11. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.

  12. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.

  13. Rice GP. The Genetic epidemiology of Multiple Sclerosis. In: Continuum. Multiple Sclerosis. Lippincott Williams & Wilkins 2004; 10(6): 28-37.

  14. Kurtzke JF, Hyllested K, Heltberg A. Multiple sclerosis in the Faeroe Islands: transmission across four epidemics. Acta Neurol Scand 1995; 91: 321-5.

  15. Fleming JO. Diagnosis and management of multiple sclerosis. 1st. Ed. Ed. Professional Communications Inc.; 2002.

  16. Noseworthy JH, LucchinettiI C, Rodriguez M, Weinshenker BG. Medical Progress: Multiple Sclerosis. N Eng J Med 2000; 343(13): 938-52.

  17. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.

  18. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.

  19. Lucchinetti C, Brueck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001; 14: 259-69.

  20. Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells and monocytes produce brainderived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role for inflammation? J Exp Med 1999; 189: 865-70.

  21. Miller JR. Multiple Sclerosis. In: Rowland LP. Merritt’s Neurology. 10th Ed. Lippincott Williams & Wilkins 2000, p. 773-92.

  22. Coyle PK. Multiple sclerosis clinical variants and differential diagnosis. In: Continuum. Multiple Sclerosis. Lippincott Williams & Wilkins 2004; 10(6): 38-73.

  23. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.

  24. Paty DW, Oger JJ, Kastrukoff LF. MRI in the diagnosis of multiple sclerosis: a perspective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988; 38: 180-5.

  25. Fasekas F, Offenbacher H, Fuchs S. Criteria of a increased specificity of MRI interpretation in elderly subjets with suspected multiple sclerosis. Neurology 1988; 38: 1822- 55.

  26. Barkhof F, Filippi M, Miller DH. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-69.

  27. Kurtzke FJ. Epidemiology of Multiple Sclerosis. Baker’s Clinical Neurology on CD-ROM. Ed. Lippincott Williams & Wilkins; 2000.

  28. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58(Suppl. 4): S3-S9.

  29. Dhib-Jalbut S. Mechanisms of interferon beta action in multiple sclerosis. Mult Scler 1997; 3: 397-401.

  30. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682-9.

  31. Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon beta in multiple sclerosis includes the upregulation of T helper 1-associated marker genes. Ann Neurol 2001; 50: 349-57.

  32. Calabresi PA, Stone LA, Bash CN, et al. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997; 48: 1446-8.

  33. Goodin DS, Frohman EM, Garmany Jr. GP, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58(2): 169-78.

  34. PRISMS Study Group. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352(9139): 1498-504.

  35. Li DKB, Paty DW, PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46(2): 197-206.

  36. PRISMS Study Group, University of British Columbia MS/ MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-b-1a in relapsing MS. Neurology 2001; 56(12): 1628-36.

  37. Panitch H, Goodin DS, Francis G, et al., for the EVIDENCE (Evidence of interferon dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group*Randomized, comparative study of interferon ß- 1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002; 59: 1496-506.

  38. Schwid SR, Thorpe J, Sharief M, et al. For the EVIDENCE (Evidence of interferon dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis. The EVIDENCE Study. Arch Neurol 2005; 62: 785-92.

  39. Freedman MS. Dose-dependent clinical and magnetic resonance imaging efficacy of interferon beta-1a in multiple sclerosis. Ann Neurol 1998; 44(6): 922. Ref Type: Abstract.

  40. Rudick R, Simonian N, Alam J, Campion M, Scaramucci J, Jones W, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266-72.

  41. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta- 1b: experience during the first three years. Neurology 1996; 47: 889-94.

  42. Aguilar RF. Interferones en Neurología. Rev Invest Clin 2000; 52(6): 665-79.

  43. Gonorazky SE. Tratamiento de esclerosis múltiple con interferón beta y acetato de glatiramer: evaluación del costo relacionado a la eficacia en Argentina. Rev Neurol Arg 2002; 27: 24-9.

  44. Cabrera-Gómez JA, López-Saura P. Interferón alfa en el tratamiento de la esclerosis múltiple. Actualización y experiencia en Cuba. Rev Neurol 1999; 28: 849-58.

  45. León C, Violante A, Arriada N, Santana HR, Corona T. El interferón beta 1-a en el tratamiento de la esclerosis múltiple con curso remitente recurrente. Primera descripción en una población mexicana. Rev Neurol 2000; 31(11): 1019-22.

  46. Rangel Guerra R, Muñoz Landeros C. Experiencia Clínica con Interferón beta 1-b en 30 pacientes con diagnóstico de esclerosis múltiple en el noreste de México. Medicina Universitaria 2004; 6(24): 182-7.




2020     |     www.medigraphic.com